OneSCD, 'A Global Partnership to Advance Equity and Transform Sickle Cell Care', was launched on 23 September 2026 in New York, on the sidelines of the 81st UN General Assembly (UNGA 81). Nigeria's government hosted the launch and India co-hosted it.
Its partners include WHO, UNICEF, Africa CDC, the World Coalition on Sickle Cell Disease and St. Jude Children's Research Hospital. It is meant to coordinate and scale existing country-led Sickle Cell Disease (SCD) programmes rather than replace them.
India was represented by Union Health Secretary Punya Salila Srivastava. Under the National Sickle Cell Anaemia Elimination Mission (2023), 7.29 crore people have been screened, over 20 lakh carriers and 2.5 lakh patients identified, and 4.93 crore sickle cell cards distributed.
SCD affects more than 7 million people worldwide, over three-quarters of them in sub-Saharan Africa. Nigeria carries the largest national burden, and in India the disease is concentrated among tribal communities.
UN specialised agency for health; co-organiser of OneSCD
UN agency for children; co-organiser. SCD kills most untreated children in Africa before age five
African Union's public health agency; co-organiser
Paediatric research hospital with a long-running SCD programme; co-organiser
Global coalition of patient groups, clinicians and advocates; co-organiser
Developed BIRSA 101 and transferred the technology to the Serum Institute of India
Announced in Union Budget 2023-24 and launched by PM Narendra Modi on 1 July 2023 at Shahdol, Madhya Pradesh. Goal: eliminate sickle cell anaemia as a public health problem by 2047.
Key: Universal screening of 7 crore people aged 0-40 in tribal areas of 278 districts across 17 high-focus states. Screening is followed by counselling, hydroxyurea treatment and digital tracking.
Issued to each person screened under NSCAEM, recording whether they are normal, a carrier or a patient.
Key: Supports pre-marital and pre-conception counselling so that two carriers are aware of the risk to their children. 4.93 crore cards had been distributed by September 2026.
India's first indigenous CRISPR-based gene therapy for SCD, launched in November 2025 by the Union Science & Technology Minister.
Key: Developed by CSIR-IGIB and licensed to the Serum Institute of India. Expected to cost about Rs 50 lakh, against Rs 20-25 crore per patient for gene therapies abroad. Clinical trials with AIIMS Delhi from 2026.
Recognised sickle-cell anaemia as a public health priority and asked affected countries and WHO to strengthen their response.
Recognised SCD as a public health problem and one of the world's foremost genetic diseases, and asked countries to raise awareness every 19 June, now World Sickle Cell Day.
59th World Health Assembly adopts WHA59.20 on sickle-cell anaemia
UNGA recognises SCD as a public health problem; 19 June becomes World Sickle Cell Day
NSCAEM launched at Shahdol, Madhya Pradesh
BIRSA 101, India's first CRISPR-based SCD gene therapy, launched
OneSCD launched at UNGA 81 in New York, with India as co-host
GS Paper II > Health; Welfare of vulnerable sections (Scheduled Tribes) | Prelims General Science (genetic disorders)
General Awareness > Government schemes; Important days; Human diseases
Global partnership for equitable Sickle Cell Disease care, launched at UNGA 81 on 23 September 2026; hosted by Nigeria and co-hosted by India
The abnormal haemoglobin, caused by a mutation in the beta-globin gene, that makes red blood cells sickle
Carrier state with one sickle gene. Usually symptom-free and protective against severe falciparum malaria. Two carriers can have an affected child